Franklin Street Advisors Inc. NC decreased its position in Idexx Laboratories Inc. (NASDAQ:IDXX) by 9.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 45,575 shares of the company’s stock after selling 4,791 shares during the period. Franklin Street Advisors Inc. NC owned approximately 0.05% of Idexx Laboratories worth $5,138,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the company. State Treasurer State of Michigan raised its position in shares of Idexx Laboratories by 0.3% in the second quarter. State Treasurer State of Michigan now owns 35,900 shares of the company’s stock worth $3,334,000 after buying an additional 100 shares in the last quarter. FCG Advisors LLC raised its position in shares of Idexx Laboratories by 4.8% in the second quarter. FCG Advisors LLC now owns 2,935 shares of the company’s stock worth $273,000 after buying an additional 135 shares in the last quarter. IFP Advisors Inc raised its position in shares of Idexx Laboratories by 18.1% in the second quarter. IFP Advisors Inc now owns 1,203 shares of the company’s stock worth $112,000 after buying an additional 184 shares in the last quarter. Calvert Investment Management Inc. raised its position in shares of Idexx Laboratories by 3.8% in the second quarter. Calvert Investment Management Inc. now owns 5,397 shares of the company’s stock worth $501,000 after buying an additional 199 shares in the last quarter. Finally, Seaward Management Limited Partnership raised its position in shares of Idexx Laboratories by 1.1% in the second quarter. Seaward Management Limited Partnership now owns 18,230 shares of the company’s stock worth $1,692,000 after buying an additional 200 shares in the last quarter. Hedge funds and other institutional investors own 91.71% of the company’s stock.

Institutional Ownership by Quarter for Idexx Laboratories (NASDAQ:IDXX)

Idexx Laboratories Inc. (NASDAQ:IDXX) traded down 0.30% during midday trading on Wednesday, hitting $112.75. 471,297 shares of the stock traded hands. Idexx Laboratories Inc. has a 52-week low of $63.48 and a 52-week high of $117.84. The stock has a 50-day moving average of $110.49 and a 200 day moving average of $101.25. The firm has a market cap of $10.11 billion, a PE ratio of 48.02 and a beta of 0.48.

Idexx Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, November 1st. The company reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.60 by $0.02. The firm earned $448.30 million during the quarter, compared to analyst estimates of $448.60 million. Idexx Laboratories had a net margin of 12.36% and a negative return on equity of 788.91%. The business’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the firm earned $0.48 EPS. Equities analysts forecast that Idexx Laboratories Inc. will post $2.38 EPS for the current year.

IDXX has been the subject of several research reports. Canaccord Genuity set a $125.00 price objective on shares of Idexx Laboratories and gave the company a “buy” rating in a research report on Saturday, October 15th. Stifel Nicolaus reiterated a “buy” rating and set a $120.00 price objective (up previously from $92.00) on shares of Idexx Laboratories in a research report on Wednesday, August 3rd. Northcoast Research upgraded shares of Idexx Laboratories from a “sell” rating to a “neutral” rating in a research report on Wednesday, August 3rd. Zacks Investment Research lowered shares of Idexx Laboratories from a “buy” rating to a “hold” rating in a research report on Tuesday, July 26th. Finally, Bank of America Corp. reiterated a “neutral” rating on shares of Idexx Laboratories in a research report on Thursday, September 29th. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Idexx Laboratories has an average rating of “Buy” and a consensus price target of $105.20.

In related news, Chairman Jonathan W. Ayers sold 40,000 shares of the business’s stock in a transaction on Wednesday, November 9th. The shares were sold at an average price of $107.85, for a total value of $4,314,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director William T. End sold 5,000 shares of the business’s stock in a transaction on Tuesday, November 8th. The stock was sold at an average price of $109.87, for a total transaction of $549,350.00. Following the completion of the sale, the director now directly owns 48,654 shares of the company’s stock, valued at approximately $5,345,614.98. The disclosure for this sale can be found here. 2.79% of the stock is currently owned by corporate insiders.

About Idexx Laboratories

5 Day Chart for NASDAQ:IDXX

Receive News & Stock Ratings for Idexx Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idexx Laboratories Inc. and related stocks with our FREE daily email newsletter.